Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Biotech Gives SBIO Its Best Month Since 2023

BY | ETF Database
8:52 am ET 07/02/26 | 11 VIEWS
Biotech stocks delivered their best single month since late 2023 in June, carrying the ALPS Medical Breakthroughs ETF (SBIO B-) to one of the top returns across the ALPS lineup.Key Takeaways: SBIO returned 18.7% in June, its best single month since December 2023. Apogee, Definium, and Oruka combined to add more than five percentage points to the index’s return. Definium surged 92.2% in June despite averaging less than 1% of the index, adding 1.58 percentage points to the return. SBIO’s underlying index returned 18.7% in June, according to VettaFi. For biotech investors, June showed exactly why clinical-stage exposure matters. Drug trial results and one $10.9 billion buyout drove most of the return. See more: Biotech ETF Index Surges 10% After Rebalance Apogee Therapeutics, Inc. (APGE) was the index’s top contributor, with its stock climbing 61.6% and adding 2.18 percentage points to the overall return, according to VettaFi. AbbVie Inc. (ABBV) announced it would acquire Apogee for roughly $10.9 billion, or $135.11 per share in cash, according to Barron’s reporting. Apogee shares jumped 47% in a single session after the deal was announced. AbbVie’s immunology segment, largely driven by Skyrizi, generated $7.3 billion in its most recent quarter.Biotech Trial Wins Drove the Other Top MoversDefinium Therapeutics, Inc. (DFTX) was the second-largest contributor despite averaging less than 1% of the index by weight. Its stock surged 92.2% and added 1.58 percentage points to the return, according to VettaFi. On June 22, Definium announced positive results from its Emerge Phase 3 study, which evaluated a single-dose treatment for major depressive disorder. Robert W. Baird analyst Christopher Chen raised his price target on the stock to $57 from $37 while maintaining an outperform rating following the results, according to reporting from TheFly. Oruka Therapeutics, Inc. (ORKA) added 1.43 percentage points after its stock gained 62.6%. Oruka reported data from its EVERLAST-A Phase 2a trial, showing 63.5% of patients with moderate-to-severe plaque psoriasis achieved full skin clearance at 16 weeks, according to Investing.com. Spyre Therapeutics, Inc. (SYRE) and MBX Biosciences, Inc. (MBX) also contributed to the month’s gain. Spyre added 0.97 of a percentage point on a 20.19% return, while MBX contributed 0.77 of a percentage point after gaining 75.41%, according to VettaFi. Celcuity, Inc. (CELC) was the month’s worst performer in the index, falling 34% and pulling 1.73 percentage points from the return. For more news, information, and analysis, visit the ETF Building Blocks Content Hub. VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.

More Commentary

Top-Performing Sector SPDRs: XLK, XLE & XLI Top The List
BY | ETF Database
9:20 am ET 07/02/26 | 17 VIEWS
ETF Spotlight: How BKGI Redefines Infrastructure Investing
BY | ETF Database
9:30 am ET 07/02/26 | 7 VIEWS
Position for a Europe Rebound With This ETF
BY | ETF Database
4:59 am ET 07/02/26 | 24 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.